Literature review identified 1,123 articles on efficacy and safety of VTE prophylaxis and 636 articles on burden
Budget impact analysis
In the base case, a 1%-point market share change from LMWH to IPC resulted in a cost reduction of $90,779 (Table 2) • A significant but not substantial saving of $12 per patient year (95% CrI: $9; $14)
• Cost savings were significant ( Figure 1 ) although the change in DVT (95% CrI: -0.63; 0.38) and PE (-0.36; 0.96) were not Rhodri JK. Saunders 1 and Audrey A. Ozols 2 1. Coreva Scientific, Freiburg, Germany; 2. Medtronic, Boulder, Colorado, USA
• Significant reductions in minor (95% CrI: -3.98; -1.88) and major (-0.90; -0.08) bleeds were apparent when using IPC in place of LMWH
• To the nearest $1000, each percentage-point increase in IPC market share reduced costs compared with LMWH by $91,000 ( Figure 1 ) and no prophylaxis by $42,000
• Cost of prophylaxis was the largest cost driver, but if LMWH was at no cost, the total cost saving with IPC was $23,339 (95% CrI: $809; $40,448) driven by reduced AEs (bleeding)
• The breakeven point was determined to be when IPC cost $357 more than LMWH per patient per 30 days of prophylaxis
• Changing AE costs did not significantly alter model findings 
CONCLUSIONS
• VTE is a significant burden to the US healthcare system
• Small changes in the methods of prophylaxis chosen will not substantially alter budgets • VTE can be "silent" with the first sign of a problem being mortality [1] • It is the leading cause of preventable inpatient death [2]
• Up to 72% of VTE cases occur after hospital discharge [3] • Failure to provide prophylaxis to at-risk patients is a medical error [1] • Multiple methods of VTE prophylaxis exist including drugs (e.g. heparin) and mechanical methods (e.g. IPC) • Little is known about the impact of different VTE prophylaxis methods on healthcare budgets
AIMS
Evaluate the current literature to estimate the US burden of VTE and the budget impact of different prophylaxis methods for healthcare payers using a standard pay for service model for total hip arthroplasty (THA) and total knee arthroplasty (TKA)
METHODS

Literature review
Structured search of PubMed was performed to identify recent publications relating to the incidence and costs of VTE and adverse events (AEs).
• Title and abstract searches and MeSH terms restricted returned hits to those specific to VTE, anticoagulation, prophylaxis, or bleeding published from 2012 onwards
• Searches were performed on September 21, 2015
• Duplicates removal and screening was performed by two reviewers using Sourcerer (Covalence Research) • Title and abstract screening against pre-defined exclusion criteria selected hits that provided cost and/or incidence data
Budget-impact model
Separate Markov models were developed in Microsoft Excel ® to simulate the onset and progression of VTE and AEs
• The semi-Markov model for VTE included: 'no VTE', 'DVT', 'PE', 'DVT and PE', 'previous VTE', 'post-thrombotic syndrome (PTS)', 'Fatal VTE', and 'death'
• The AE Markov model included: 'no AE', 'minor bleed', 'major bleed', 'fatal bleed', 'wound infection' and 'heparin-induced thrombocytopenia (HIT)'
• Flexible Markov model order can assess structural uncertainty • Death was consolidated between the two Markov models • The AE model only ran during the duration of prophylaxis
• Prophylaxis options included: low-molecular-weight heparin (LMWH), unfractionated heparin, rivaroxaban, apixaban, warfarin, IPC, and no prophylaxis 
Scenario analyses
• Using market share and prophylaxis cost data provided by a US payer, transferring all patients to IPC would reduce total costs by $7.8 million, a 42% reduction (Figure 2 ) [20] • In an analysis using German cost and incidence data, • Prophylaxis duration was 30 days as per guidelines [5] • DVT and PE occurred at a rate of 1.8% and 0.7%, respectively, per 42 days [6] • Minor and major bleeds occurred at a rate of 9.9% per 42 days and 1.7% per 11 days, respectively [6, 7] • Event costs were derived from the literature review and adjusted to 2014 USD using the US healthcare-specific PPI
• Intervention costs and market share were informed by Analy$ource, literature review and current pricing [4, 8, 9] • A percentage point of market share was moved from LMWH to IPC
• The model time horizon was 1 year with no cost discounting
Sensitivity analyses
Probabilistic analyses evaluated the robustness of results to changes in all input parameters via sampling
• Results from 500 simulations are presented with the median and 95% credible intervals (CrI)
• One-way analysis tested the impact of other event cost options Change in outcome from baseline with IPC, %
